Activated AMPK attenuates cardiac hypertrophy in rats through increas- ing myocardial fatty acid oxidation

Yin Ran, Dong Yugang, Li Hongliang, Liu Dan

Journal not recorded26 Nov 2010

PepBankPUB-94291642

Ask about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse.

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Mechanism
In rats with TAC, AICAR increased PPAR alpha mRNA expression versus controls.
In plain wordsIn rats with cardiac hypertrophy, AICAR increased PPAR alpha gene expression versus controls.
Peptide
AICAR (acadesine)
Outcome
IncreasePPAR alpha mRNA
Study
ratn: not reported in source
TAC cardiac hypertrophy
Comparator
control group
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
0.5 mg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
Compared with control group, treatment of rats subjected to TAC with AICAR significantly increased the mRNA expression of PPAR#alpha# and CPT - I
2 context sentences(design, population, supporting numbers)
Summary · context
The model of cardiac hypertrophy was produced by banding abdominal aorta transaortic constriction, TAC in male Sprague - Dawley rats.
Summary · context
Echocardiographic and ventricular remodeling parameters, free fatty acid concentration in blood serum and myocardium, and expression of peroxisome proliferator - activated receptorPPARct and carnitine palmityl transferase CPT- I mRNA were investigated after treatment of AICAR or vehicle for 7 weeks.
Report a problemFND-9429164201
02AnimalAnimal study (in vivo)Mechanism
In rats with TAC, AICAR increased CPT-I mRNA expression versus controls.
In plain wordsIn rats with cardiac hypertrophy, AICAR increased CPT-I gene expression versus controls.
Peptide
AICAR (acadesine)
Outcome
IncreaseCPT-I mRNA
Study
ratn: not reported in source
TAC cardiac hypertrophy
Comparator
control group
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
0.5 mg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
Compared with control group, treatment of rats subjected to TAC with AICAR significantly increased the mRNA expression of PPAR#alpha# and CPT - I
2 context sentences(design, population, supporting numbers)
Summary · context
The model of cardiac hypertrophy was produced by banding abdominal aorta transaortic constriction, TAC in male Sprague - Dawley rats.
Summary · context
Echocardiographic and ventricular remodeling parameters, free fatty acid concentration in blood serum and myocardium, and expression of peroxisome proliferator - activated receptorPPARct and carnitine palmityl transferase CPT- I mRNA were investigated after treatment of AICAR or vehicle for 7 weeks.
Report a problemFND-9429164202
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAC, AICAR decreased blood free fatty acid concentrations versus controls.
In plain wordsIn rats with cardiac hypertrophy, AICAR reduced blood free fatty acids versus controls.
Peptide
AICAR (acadesine)
Outcome
DecreaseBlood free fatty acids
Study
ratn: not reported in source
TAC cardiac hypertrophy
Comparator
control group
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 mg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
and subsequently decreased free fatty acid concentration in blood and myocardium,
2 context sentences(design, population, supporting numbers)
Summary · context
The model of cardiac hypertrophy was produced by banding abdominal aorta transaortic constriction, TAC in male Sprague - Dawley rats.
Summary · context
Echocardiographic and ventricular remodeling parameters, free fatty acid concentration in blood serum and myocardium, and expression of peroxisome proliferator - activated receptorPPARct and carnitine palmityl transferase CPT- I mRNA were investigated after treatment of AICAR or vehicle for 7 weeks.
Report a problemFND-9429164203
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAC, AICAR decreased myocardial free fatty acid concentrations versus controls.
In plain wordsIn rats with cardiac hypertrophy, AICAR reduced heart muscle free fatty acids versus controls.
Peptide
AICAR (acadesine)
Outcome
DecreaseMyocardial free fatty acids
Study
ratn: not reported in source
TAC cardiac hypertrophy
Comparator
control group
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 mg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
and subsequently decreased free fatty acid concentration in blood and myocardium,
2 context sentences(design, population, supporting numbers)
Summary · context
The model of cardiac hypertrophy was produced by banding abdominal aorta transaortic constriction, TAC in male Sprague - Dawley rats.
Summary · context
Echocardiographic and ventricular remodeling parameters, free fatty acid concentration in blood serum and myocardium, and expression of peroxisome proliferator - activated receptorPPARct and carnitine palmityl transferase CPT- I mRNA were investigated after treatment of AICAR or vehicle for 7 weeks.
Report a problemFND-9429164204
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAC, AICAR improved echocardiographic characteristics versus controls.
In plain wordsIn rats with cardiac hypertrophy, AICAR improved heart ultrasound characteristics versus controls.
Peptide
AICAR (acadesine)
Outcome
Direction not reportedEchocardiographic characteristics
Study
ratn: not reported in source
TAC cardiac hypertrophy
Comparator
control group
Outcome group
Heart function · Cardiovascular
Studied dose
0.5 mg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
improved echocardiographic characteristics,
2 context sentences(design, population, supporting numbers)
Summary · context
The model of cardiac hypertrophy was produced by banding abdominal aorta transaortic constriction, TAC in male Sprague - Dawley rats.
Summary · context
Echocardiographic and ventricular remodeling parameters, free fatty acid concentration in blood serum and myocardium, and expression of peroxisome proliferator - activated receptorPPARct and carnitine palmityl transferase CPT- I mRNA were investigated after treatment of AICAR or vehicle for 7 weeks.
Report a problemFND-9429164205
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAC, AICAR reduced the increase in heart weight/body weight ratio versus controls.
In plain wordsIn rats with cardiac hypertrophy, AICAR reduced the rise in heart weight relative to body weight versus controls.
Peptide
AICAR (acadesine)
Outcome
DecreaseHeart weight/body weight ratio
Study
ratn: not reported in source
TAC cardiac hypertrophy
Comparator
control group
Outcome group
Heart function · Cardiovascular
Studied dose
0.5 mg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
and reduced the increases in the heart weight/body weight ratio and myocyte diameter.
2 context sentences(design, population, supporting numbers)
Summary · context
The model of cardiac hypertrophy was produced by banding abdominal aorta transaortic constriction, TAC in male Sprague - Dawley rats.
Summary · context
Echocardiographic and ventricular remodeling parameters, free fatty acid concentration in blood serum and myocardium, and expression of peroxisome proliferator - activated receptorPPARct and carnitine palmityl transferase CPT- I mRNA were investigated after treatment of AICAR or vehicle for 7 weeks.
Report a problemFND-9429164206
07AnimalAnimal study (in vivo)Efficacy outcome
In rats with TAC, AICAR reduced the increase in myocyte diameter versus controls.
In plain wordsIn rats with cardiac hypertrophy, AICAR reduced heart cell enlargement versus controls.
Peptide
AICAR (acadesine)
Outcome
DecreaseMyocyte diameter
Study
ratn: not reported in source
TAC cardiac hypertrophy
Comparator
control group
Outcome group
Heart function · Cardiovascular
Studied dose
0.5 mg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
Summary
and reduced the increases in the heart weight/body weight ratio and myocyte diameter.
2 context sentences(design, population, supporting numbers)
Summary · context
The model of cardiac hypertrophy was produced by banding abdominal aorta transaortic constriction, TAC in male Sprague - Dawley rats.
Summary · context
Echocardiographic and ventricular remodeling parameters, free fatty acid concentration in blood serum and myocardium, and expression of peroxisome proliferator - activated receptorPPARct and carnitine palmityl transferase CPT- I mRNA were investigated after treatment of AICAR or vehicle for 7 weeks.
Report a problemFND-9429164207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Research article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.